Company Profile

**Industry Sector:** Medical Devices and Research Products

**Company Overview:** HepatoSys is dedicated to the development of processes for the restoration of function to currently discarded human organs to allow their use in therapeutic transplantation or the provision of viable human cells for research and testing.

**Target Market(s):** The target market for the transplantation technology will be medical centers with transplant programs. The target market for viable human cells will be research and toxicity testing in both academic and pharmaceutical labs.

Management

**Leadership:**
- Elizabeth Miescher-Clemens PhD, President and COO
- Mark G. Clemens PhD, Vice president and Chief Scientific Officer
- Charles C.Y Lee PhD, Vice president and Director of Research Development
- Kristen Rogentine-Lee PhD, Vice President and Director of Personnel

Key Value Drivers

**Technology:** HepatoSys' core technology is a solution and process that is able to restore function to organs from cardiac death donors that have incurred ischemic damage to the extent that they are currently discarded. The two current applications are to increase the number of donor livers available for transplant and to restore function to discarded human livers so that high-quality hepatocytes can be isolated for research and testing purposes.

**Competitive Advantage:** HeptoSys' technology is based on strong preclinical data. Our research team of a liver disease expert, a bioengineer and a transplant surgeon has developed the technology with focus on application. We have access to discarded human livers allowing us to perfect our cell isolation technique in the within this year.

**Plan & Strategy:** Proof of concept for isolation of hepatocytes from discarded human livers is first priority. We plan to license this application to provide a revenue stream to support studies to bring the transplant application to clinical trials.

*Technology funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and being commercialized under the NIH-CAP*

Product Pipeline

- **Isolation of human hepatocytes for research.**
  - Optimize in rat model: summer 2012
  - Proof of concept in human liver: fall 2012
  - Develop turnkey system: Spring 2013
  - Partnership or license: fall 2013

- **Restore organs for transplant.**
  - Prevention of primary graft nonfunction in swine mode: Summer 2012
  - Prevention of biliary complications: Spring 2013
  - Seek clinical test sites: Summer 2013